Oncology

#Animal models #Biochemistry #Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Molecular medicine #Oncology #Orphan drugs #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Natural Killer Cells – How NK Cell Therapy Will Transform Immunotherapy

Natural Killer Cells - How NK Cell Therapy Will Transform Immunotherapy By Dr Azusa Tanaka and Dr Michael Seiler Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment and the battle… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Lead discovery #Molecular medicine #Oncology #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

The Cancer Conundrum – Increasing Clinical Success In Early Stage Drug Discovery

The Cancer Conundrum - Increasing Clinical Success In Early Stage Drug Discovery By Lubna Hussain This article focuses on increasing clinical success in early stage drug discovery, by implementing improved methodologies in the early phase & using primary cells and 3D culture models to enhance cancer drug discovery. The high… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Metabolomics #Molecular medicine #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1)

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development. Tesla intends to implement and… Read More

#Archive

#Analysis #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Cellular assays #Chemical engineering #Drug development #Drug discovery #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Screening #Stem cells #System biology

Kinases – Shedding Light on Kinase Drug Discovery

Kinases - Shedding Light on Kinase Drug Discovery By Dr Gary Allenby This article discusses the application of new assay technologies to shed light on kinase drug discovery. The human kinome comprises 518 known protein kinases and more than 20 lipid kinases. Nearly all aspects of control within a cell… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug targets #Genetics / genomes #High Content Screening #Imaging #Immunology #Lead optimisation #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #System biology #Target validation #Therapeutics

Practicalities of Conducting Replication Studies in Preclinical Cancer Biology

Practicalities of Conducting Replication Studies in Preclinical Cancer Biology By Dr Nicole Perfito, Dr Rachel Tsui & Dr Elizabeth Iorns The first results for the Reproducibility Project: Cancer Biology, offer insights into the time and cost of conducting replication studies in preclinical cancer biology. While many agree that developing a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biobanking #Biomarkers #Business #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing

The Use of Next-Generation Sequencing in Drug Development

The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More

#Archive

#Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Immunology #Medicinal chemistry #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Therapeutic Antibodies – New tools to enhance the antibody drug pipeline

Therapeutic Antibodies - New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to… Read More

#Archive

#Academic #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #RNA #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Epigenetics – Unlocking The Potential for Personalised Medicine

By Dr Jason Mellad The sequencing of the human genome in 2003 signalled the dawn of an exciting new era for genetic medicine. Yet almost 15 years later it has become clear that our genes alone cannot predict our susceptibility to most complex diseases or fully explain fundamental aspects of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

Oral Peptide Therapeutics – A Holy Grail or Quixotic Quest?

Oral Peptide Therapeutics - A Holy Grail or Quixotic Quest? By Dr Paul Shields Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and peptides are the building blocks of life… Read More

#Exclusive Content

#Academic #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Novel Drug Targets From Phenotypic Screening

Novel Drug Targets From Phenotypic Screening By Dr Jim Freeth, Dr Elizabeth Kingsley & Jo Soden Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biologics / Biotechnology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene editing #Immunology #Lead discovery #Microbiome #Oncology #Pathology #Pharmacology #Preclinical #RNA #Stem cells #System biology #Systems biology #Target validation

How The B6 Mouse Strain is Revolutionising Drug Discovery

How The B6 Mouse Strain is Revolutionising Drug Discovery By Dr Philip Dube Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research. Understanding the B6… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Pathology #Pharmokinetics #Preclinical #Regulatory #RNA #Stem cells #Target validation #Toxicology

The Rise of Immunotherapies – Strategies to Accelerate Their Advance Into Clinical Trials

The Rise of Immunotherapies - Strategies to Accelerate Their Advance Into Clinical Trials By Edward Cribb The striking rise of immunotherapies in the past decade has had a transformative effect on the prospects for the treatment of patients with cancer. Also referred to as biologic therapies, immunotherapies are a new… Read More

#Archive

#Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Oncology #Organic chemistry #Pathology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design

The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design By Simon Pearce Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #Screening #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Raising The Bar On The Biologics Potential

Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Oncology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

3D Cell Culture – A Rapidly Emerging Technique for Drug Discovery

3D Cell Culture - A Rapidly Emerging Technique for Drug Discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Imaging #Immunology #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired, efficacious but yet safe effect in… Read More

#Archive